LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 39

Search options

  1. Article ; Online: Editorial Comment.

    Gadzinski, Adam J / Gore, John L

    The Journal of urology

    2022  Volume 208, Issue 4, Page(s) 854

    Language English
    Publishing date 2022-08-03
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1097/JU.0000000000000805.01
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Editorial Comment.

    Gadzinski, Adam J / Wright, Jonathan L

    The Journal of urology

    2020  Volume 204, Issue 4, Page(s) 683

    MeSH term(s) Carcinoma, Transitional Cell ; Cystectomy ; Humans ; Urinary Bladder ; Urologic Neoplasms
    Language English
    Publishing date 2020-07-23
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1097/JU.0000000000001071.01
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Telehealth in urology after the COVID-19 pandemic.

    Gadzinski, Adam J / Ellimoottil, Chad

    Nature reviews. Urology

    2020  Volume 17, Issue 7, Page(s) 363–364

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; Telemedicine ; Urology
    Keywords covid19
    Language English
    Publishing date 2020-05-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2493737-X
    ISSN 1759-4820 ; 1759-4812
    ISSN (online) 1759-4820
    ISSN 1759-4812
    DOI 10.1038/s41585-020-0336-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Risk stratification metrics for bladder cancer: Comprehensive Geriatric Assessments.

    Gadzinski, Adam J / Psutka, Sarah P

    Urologic oncology

    2020  Volume 38, Issue 9, Page(s) 725–733

    Abstract: Despite advances in surgical technique and perioperative care pathways, complication rates following radical cystectomy for bladder cancer remain high and perioperative outcomes for elderly patients are suboptimal. Furthermore, subjective risk ... ...

    Abstract Despite advances in surgical technique and perioperative care pathways, complication rates following radical cystectomy for bladder cancer remain high and perioperative outcomes for elderly patients are suboptimal. Furthermore, subjective risk assessments of patients with bladder cancer, with a high prevalence of complex comorbidity burden and risk of frailty, may result in undertreatment of patients assumed to be poor operative candidates. A critical component of preoperative patient counseling and treatment selection is accurate and objective preoperative risk appraisal. Comprehensive Geriatric Assessments are multi-domain evaluations of the medical, functional, and psychosocial aspects of health designed specifically for use in elderly patients with the objective of identifying vulnerabilities that may be targeted with interventions for improvement. While currently recommended by multiple guideline bodies for use in the preoperative evaluation of elderly patients with bladder cancer there is a paucity of data describing their use in contemporary clinical practice. Herein, then, we will describe the components of a Comprehensive Geriatric Assessments and propose strategies for their integration into the preoperative surgical workflow.
    MeSH term(s) Aged ; Benchmarking ; Cystectomy ; Forecasting ; Geriatric Assessment/methods ; Humans ; Risk Assessment ; Urinary Bladder Neoplasms/surgery
    Language English
    Publishing date 2020-02-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1336505-8
    ISSN 1873-2496 ; 1078-1439
    ISSN (online) 1873-2496
    ISSN 1078-1439
    DOI 10.1016/j.urolonc.2020.01.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?

    Chang, Edward K / Gadzinski, Adam J / Nyame, Yaw A

    Asian journal of urology

    2021  Volume 8, Issue 4, Page(s) 343–353

    Abstract: Objective: There is no consensus on the role of biomarkers in determining the utility of prostate biopsy in men with elevated prostate-specific antigen (PSA). There are numerous biomarkers such as prostate health index, 4Kscore, prostate cancer antigen ... ...

    Abstract Objective: There is no consensus on the role of biomarkers in determining the utility of prostate biopsy in men with elevated prostate-specific antigen (PSA). There are numerous biomarkers such as prostate health index, 4Kscore, prostate cancer antigen 3, ExoDX, SelectMDx, and Mi-Prostate Score that may be useful in this decision-making process. However, it is unclear whether any of these tests are accurate and cost-effective enough to warrant being a widespread reflex test following an elevated PSA. Our goal was to report on the clinical utility of these blood and urine biomarkers in prostate cancer screening.
    Methods: We performed a systematic review of studies published between January 2000 and October 2020 to report the available parameters and cost-effectiveness of the aforementioned diagnostic tests. We focus on the negative predictive value, the area under the curve, and the decision curve analysis in comparing reflexive tests due to their relevance in evaluating diagnostic screening tests.
    Results: Overall, the biomarkers are roughly equivalent in predictive accuracy. Each test has additional clinical utility to the current diagnostic standard of care, but the added benefit is not substantial to justify using the test reflexively after an elevated PSA.
    Conclusions: Our findings suggest these biomarkers should not be used in binary fashion and should be understood in the context of pre-existing risk predictors, patient's ethnicity, cost of the test, patient life-expectancy, and patient goals. There are more recent diagnostic tools such as multi-parametric magnetic resonance imaging, polygenic single-nucleotide panels, IsoPSA, and miR Sentinel tests that are promising in the realm of prostate cancer screening and need to be investigated further to be considered a consensus reflexive test in the setting of prostate cancer screening.
    Language English
    Publishing date 2021-06-23
    Publishing country Singapore
    Document type Journal Article ; Review
    ZDB-ID 2831144-9
    ISSN 2214-3882
    ISSN 2214-3882
    DOI 10.1016/j.ajur.2021.06.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Telehealth in urology after the COVID-19 pandemic

    Gadzinski, Adam J. / Ellimoottil, Chad

    Nature Reviews Urology

    2020  Volume 17, Issue 7, Page(s) 363–364

    Keywords Urology ; covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2493737-X
    ISSN 1759-4820 ; 1759-4812
    ISSN (online) 1759-4820
    ISSN 1759-4812
    DOI 10.1038/s41585-020-0336-6
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: Prostate Cancer Markers.

    Gadzinski, Adam J / Cooperberg, Matthew R

    Cancer treatment and research

    2018  Volume 175, Page(s) 55–86

    Abstract: Diagnostic biomarkers derived from blood, urine, or prostate tissue provide additional information beyond clinical calculators to determine the risk of detecting high-grade prostate cancer. Once diagnosed, multiple markers leverage prostate cancer biopsy ...

    Abstract Diagnostic biomarkers derived from blood, urine, or prostate tissue provide additional information beyond clinical calculators to determine the risk of detecting high-grade prostate cancer. Once diagnosed, multiple markers leverage prostate cancer biopsy tissue to prognosticate clinical outcomes, including adverse pathology at radical prostatectomy, disease recurrence, and prostate cancer mortality; however the clinical utility of some outcomes to patient decision making is unclear. Markers using tissue from radical prostatectomy specimens provide additional information about the risk of biochemical recurrence, development of metastatic disease, and subsequent mortality beyond existing multivariable clinical calculators (the use of a marker to simply sub-stratify risk groups such as the NCCN groups is of minimal value). No biomarkers currently available for prostate cancer have been prospectively validated to be predict an improved clinical outcome for a specific therapy based on the test result; however, further research and development of these tests may produce a truly predictive biomarker for prostate cancer treatment.
    MeSH term(s) Biomarkers, Tumor/blood ; Humans ; Male ; Prostatectomy ; Prostatic Neoplasms/diagnosis ; Risk Factors
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2018-08-28
    Publishing country United States
    Document type Journal Article
    ISSN 0927-3042
    ISSN 0927-3042
    DOI 10.1007/978-3-319-93339-9_3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Measuring quality of urology care using a qualified clinical data registry.

    Gadzinski, Adam J / Cooperberg, Matthew R

    Current opinion in urology

    2018  Volume 28, Issue 4, Page(s) 329–335

    Abstract: Purpose of review: Qualified clinical data registries (QCDRs) serve as a framework for quality improvement efforts, clinical research endeavors, and participation in reimbursement incentive programs. However, the measurement of quality and the ... ...

    Abstract Purpose of review: Qualified clinical data registries (QCDRs) serve as a framework for quality improvement efforts, clinical research endeavors, and participation in reimbursement incentive programs. However, the measurement of quality and the recommendations to guide QCDRs in developing new quality measures is a complex process. In this review, we highlight the government policies that lead to the creation of QCDRs, how QCDR quality measures are developed, and the current QCDRs that focus on urological care.
    Recent findings: QCDRs facilitate participation in the merit-based incentive payment system for reimbursement adjustments. Most QCDRs leverage existing clinical guidelines in the development of new quality measures. In 2018, there are four urology QCDRs with quality measures for many urological conditions. These QCDRs form the infrastructure for quality improvement and provide new resources for research endeavors.
    Summary: Quality measurement within QCDRs will allow urologists to focus improvement efforts to deliver high-quality urological care while also facilitating reimbursement incentives and creating novel research datasets.
    MeSH term(s) Outcome Assessment (Health Care)/legislation & jurisprudence ; Outcome Assessment (Health Care)/statistics & numerical data ; Policy ; Quality of Health Care/legislation & jurisprudence ; Quality of Health Care/statistics & numerical data ; Registries/statistics & numerical data ; Reimbursement, Incentive ; United States ; Urology/economics ; Urology/legislation & jurisprudence ; Urology/organization & administration
    Language English
    Publishing date 2018-05-29
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/MOU.0000000000000511
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Patient-centered outcomes of telehealth for the care of rural-residing patients with urologic cancer.

    Dwyer, Erin R / Holt, Sarah K / Wolff, Erika M / Stewart, Blair / Katz, Ronit / Reynolds, Jason / Gadzinski, Adam J / Gore, John L

    Cancer

    2023  Volume 129, Issue 18, Page(s) 2887–2892

    Abstract: Background: Patients residing in rural areas with urologic cancers confront significant obstacles in obtaining oncologic care. In the Pacific Northwest, a sizeable portion of the population lives in a rural county. Telehealth offers a potential access ... ...

    Abstract Background: Patients residing in rural areas with urologic cancers confront significant obstacles in obtaining oncologic care. In the Pacific Northwest, a sizeable portion of the population lives in a rural county. Telehealth offers a potential access solution.
    Methods: Patients receiving urologic care through telehealth or an in-person appointment at the Fred Hutchinson Cancer Center in Seattle, Washington, were surveyed to assess appointment-related satisfaction and travel costs. Patients' residences were classified as rural or urban based on their self-reported ZIP code. Median patient satisfaction scores and appointment-related travel costs were compared by rural versus urban residence within telehealth and in-person appointment groups using Wilcoxon signed-rank or χ
    Results: A total of 1091 patients seen for urologic cancer care between June 2019 and April 2022 were included, 28.7% of which resided in a rural county. Patients were mostly non-Hispanic White (75%) and covered by Medicare (58%). Among rural-residing patients, telehealth and in-person appointment groups had the same median satisfaction score (61; interquartile ratio, 58, 63). More rural-residing than urban-residing patients in the telehealth appointment groups strongly agreed that "Considering the cost and time commitment of my appointment, I would choose to meet with my provider in this setting in the future" (67% vs. 58%, p = .03). Rural-residing patients with in-person appointments carried a higher financial burden than those with telehealth appointments (medians, $80 vs. $0; p <.001).
    Conclusions: Appointment-related costs are high among rural-residing patients traveling for urologic oncologic care. Telehealth provides an affordable solution that does not compromise patient satisfaction.
    MeSH term(s) Humans ; Aged ; United States ; Medicare ; Telemedicine ; Patient Satisfaction ; Urologic Neoplasms/therapy ; Patient-Centered Care
    Language English
    Publishing date 2023-05-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.34848
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top